Trial · NCT00662012

Sodium Stibogluconate Treatment of Leishmaniasis

NCT00662012, Phase 2, Completed, U.S. Army Medical Research and Development Command; results first posted 2017-03-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Sodium Stibogluconate Treatment of Leishmaniasis. Trials, record NCT00662012. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00662012

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Sodium Stibogluconate Treatment of Leishmaniasis
NCT number: NCT00662012
Status: Completed
Phases: Phase 2
Enrollment: 414 participants, actual
Lead sponsor: U.S. Army Medical Research and Development Command
Conditions: Leishmaniasis
Interventions: Sodium Stibogluconate (SSG)
First posted: 2008-04-21
Last updated: 2021-02-12
Results first posted: 2017-03-09

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Primary Safety Endpoint - Frequency of Complications of Therapy	5 years	The primary safety endpoint is the frequency of complications of therapy
Secondary	Improvement of Lesions, Resolution of Fever and Lab Abnormalities for Visceral Leishmaniasis and Regression of Mucosal Lesions .	5 years	Improvement of lesions for cutaneous leishmanias, resolution of fever and lab abnormalities for visceral leishmaniasis and regression of mucosal lesions for mucocutaneous disease.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Primary Safety Endpoint - Frequency of Complications of Therapy	5 years	Analysis was per protocol	participants	NUMBER
SECONDARY	Improvement of Lesions, Resolution of Fever and Lab Abnormalities for Visceral Leishmaniasis and Regression of Mucosal Lesions .	5 years	Analysis per protocol	participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Primary Safety Endpoint - Frequency of Complications of Therapy	SSG 20 mg/kg		414		participants
Improvement of Lesions, Resolution of Fever and Lab Abnormalities for Visceral Leishmaniasis and Regression of Mucosal Lesions .	SSG 20 mg/kg		414		participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	SSG 20 mg/kg	414
Overall Study	COMPLETED	SSG 20 mg/kg	327
Overall Study	NOT COMPLETED	SSG 20 mg/kg	87

Source ClinicalTrials.gov

Adverse events195

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	SSG 20 mg/kg	7	414	7
other	Leukopenia	Blood and lymphatic system disorders	SSG 20 mg/kg	21	414	21
other	Lymphadenopathy	Blood and lymphatic system disorders	SSG 20 mg/kg	59	414	59
other	Thrombocytopenia	Blood and lymphatic system disorders	SSG 20 mg/kg	10	414	10
other	Bundle Branch Block Left	Cardiac disorders	SSG 20 mg/kg	4	414	4
other	Bundle Branch Block Right	Blood and lymphatic system disorders	SSG 20 mg/kg	22	414	22
other	Conduction Disorder	Cardiac disorders	SSG 20 mg/kg	9	414	9
other	Dilatation Atrial	Cardiac disorders	SSG 20 mg/kg	8	414	8
other	Palpitations	Cardiac disorders	SSG 20 mg/kg	9	414	9
other	Sinus Tachycardia	Cardiac disorders	SSG 20 mg/kg	6	414	6

1 to 10 of 195Source ClinicalTrials.gov

See all 195 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	SSG 20 mg/kg
Total, other adverse events	SSG 20 mg/kg	414	414
Total, serious adverse events	SSG 20 mg/kg	17	414

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00662012

GET https://conductscience.org/api/trials/v1/NCT00662012/events?page=2

API reference For AI assistants